Status:
COMPLETED
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of sunitinib combined with docetaxel versus docetaxel, administered as first-line treatment, in patients with unresecta...
Eligibility Criteria
Inclusion
- Breast cancer with evidence of unresectable locally recurrent, or metastatic disease
- Her-2 negative tumors
Exclusion
- Patients for whom docetaxel is contraindicated
- Clinical presentation of inflammatory carcinoma with no other measurable disease
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
594 Patients enrolled
Trial Details
Trial ID
NCT00393939
Start Date
February 1 2007
End Date
July 1 2011
Last Update
July 19 2012
Active Locations (144)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Berkely, California, United States, 94704
2
Pfizer Investigational Site
Shreveport, Louisiana, United States, 71103
3
Pfizer Investigational Site
Beaumont, Texas, United States, 77701
4
Pfizer Investigational Site
Burleson, Texas, United States, 76028